ArticleMedicine2020

Switching from originator infliximab to biosimilar infliximab in Japanese patients with rheumatoid arthritis achieving clinical remission (the IFX-SIRIUS study I): Study protocol for an interventional, multicenter, open-label, single-arm and noninferiority clinical trial with clinical, ultrasound, and biomarker assessments.

Shin-Ya Kawashiri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.